Scilex Holding Co

Scilex Holding Company (Nasdaq: SCLX) is a specialty pharmaceutical company focused on non-opioid pain management that completed its business combination with Vickers Vantage Corp. I, sponsored by Vickers Capital Group, in 2022. Operating in the healthcare sector, the company markets ZTlido, an FDA-approved lidocaine topical system for post-herpetic neuralgia pain relief, and continues to advance additional analgesic candidates through its pipeline. On December 16, 2025, Scilex filed an S-1 registration statement with the SEC under accession number 0001193125-25-319720, reflecting continued capital markets activity for the post-merger company. Sign up on SpacDesk for full filing history, deal metrics, and ongoing coverage of SCLX and the broader de-SPAC universe.